GLP-1 Meds May Lower Anxiety & Depression: New Research
Discover how GLP-1 medications like Wegovy and Ozempic may also reduce the risk of depression and anxiety, according to recent research.
R&D
Read More
Promising Results for Structure Therapeutics’ Oral Diabetes and Obesity Pill in Mid-Stage Trial
Unlike the existing GLP-1 agonists such as Wegovy, Ozempic and Zepbound, which require injections, GSBR-1290 offers the convenience of oral administration.
First-Ever Case of Rhabdomyolysis Linked to Semaglutide: Case Report
To date, there have been no reported cases associating GLP-1 agonists with rhabdomyolysis, making this revelation a significant milestone in medical research.
GLP-1 Drugs Might Also Aid Sleep Apnea
Following the initiation of Ozempic, people previously reliant on CPAP are seeing remarkable improvements in their symptoms of sleep apnea.
Study: Semaglutide’s Promising Role in Alcohol Use Disorder
The first evidence of semaglutide’s specific efficacy in alleviating symptoms of Alcohol Use Disorder (AUD) has been published in The Journal of Clinical Psychiatry.
Amgen and Viking Therapeutics Set to Join the Obesity Drug Arena
Amgen and Viking are developing obesity medications that show promise in early trials, with Amgen’s drug demonstrating a 14.5% weight loss over 12 weeks and Viking’s achieving an 8% reduction over 28 days.
Pfizer Halts Development of Obesity Drug Danuglipron Amid High Side Effect Rates
Pfizer has decided to halt the advancement of danuglipron following a challenging Phase 2b clinical trial, primarily the high incidence of adverse side effects.
Study: GLP-1 Receptor Agonists Impact on Bowel Preparation for Colonoscopy
A recent study published in The American Journal of Gastroenterology has revealed a significant association between GLP-1RAs and lower quality of bowel prep for colonoscopies.
Biohaven Trying to Launch GLP-1 Drug That Saves Muscles
While GLP-1 agonists are known for their effective weight loss results, they come with significant drawbacks, including loss of lean muscle mass. Taldefgrobep alfa, a myostatin inhibitor licensed from Bristol Myers Squibb, stands apart by targeting not just fat loss but also muscle preservation.